Diana Brainard compensation by year
Kalaris Therapeutics Summary Compensation Table · all 4 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Salary | $365,000 | $604,992 | $623,432 | $610,638 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $4,748,000 | $3,899,006 | $2,211,125 | $0 |
| Option awards | $9,085,643 | $4,327,381 | $3,209,186 | $0 |
| Non-equity incentive | $350,400 | $361,800 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $587,078 | $12,200 | $13,200 | $2,418,031 |
| Total | $15,136,121 | $9,205,379 | $6,056,943 | $3,028,669 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kalaris Therapeutics, Inc. DEF 14A filed July 1, 2025, accession 0001193125-25-153439, and prior-year filings.
How this page was built: the Kalaris Therapeutics, Inc. filed document, accession 0001193125-25-153439. Every figure is read from that document and cited to the page and table it appears in. Filed July 1, 2025.
Kalaris Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Diana Brainard · this page | Former Chief Executive Officer | $3,028,669 |
| Andrew Oxtoby | President and Chief Executive Officer | $1,965,153 |
| Brett Hagen | Chief Accounting Officer and AlloVir’s former Chief Accounting Officer | $796,311 |
| Edward Miller | Former General Counsel and Secretary | $645,693 |
| Vikas Sinha | AlloVir’s Former Chief Executive Officer, President and Chief Financial Officer | $544,400 |
Board service
Kalaris Therapeutics board · FY2023How this board is paid
Company policy: Kalaris Therapeutics pays directors a $40,000 cash retainer. As stated in Kalaris Therapeutics's FY2023 proxy.
The full Kalaris Therapeutics compensation record
free company briefThis page is one person within Kalaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kalaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.